Research Articles - Retinitis Pigmentosa
- By genetically reprogramming rods to become like cones, researchers from the Washington University School of Medicine in St. Louis may have found an innovative way to treat vision-robbing retinal diseases like retinitis pigmentosa (RP). While their research is at an early stage in mice, it has revealed valuable clues about how to potentially save vision in people. Results of the study were published in a recent online edition of Proceedings of the National Academy of Sciences.
ReNeuron, a stem-cell therapy development company in the United Kingdom, has been granted an orphan designation by the U.S. Food and Drug Administration (FDA) and the European Commission for its emerging retinitis pigmentosa (RP) treatment, known as ReN003. Given to potential treatments for rare conditions that are life-threatening or chronically debilitating, “orphan” status provides a
A Foundation-funded research team led by Dr. Eliot Berson found that adults with retinitis pigmentosa (RP) who, on average, ate one to two three-ounce servings of omega-3 rich fish per week while receiving a supplement of vitamin A palmitate had a 40 percent slower rate of visual acuity loss per year than those taking vitamin A alone. Results of the study were published in the February 13, 2012, online edition of the Archives of Ophthalmology.
The Foundation Fighting Blindness has updated its information on the combined treatment regimen of vitamin A palmitate, oily fish (DHA) and lutein, which can slow vision loss in people with retinitis pigmentosa (RP) and Usher syndrome types 2 and 3. The new information replaces the Vitamin A Packet previously provided by the Foundation.
The treatment regimen is based on three peer-reviewed, Foundation-funded clinical studies conducted by Dr. Eliot Berson and his colleagues at the
The Argus II retinal prosthesis, a device that can restore some vision to people who are blind from advanced retinitis pigmentosa (RP), has received U.S. market approval from theFood and Drug Administration (FDA). Developed by Second Sight Medical Products, the device will be available later this year in approximately 10 clinical centers across the country. In 2011, the Argus II received marketing approval in Europe. Also known as a “bionic retina,” it is currently the world’s only retinal
The Alpha IMS, a subretinal implant developed by Retina Implant AG of Reutlingen, Germany, has been granted European marketing approval. The device received a CE Mark, a regulatory designation for meeting European safety and reliability standards. Also known as an artificial or bionic retina, the Alpha IMS has
An artificial retina developed by Retina Implant AG of Reutlingen, Germany, has restored meaningful vision to most of the nine blind people — eight with retinitis pigmentosa, one with cone-rod dystrophy — enrolled in a clinical trial. Five of the participants recognized objects such as door knobs, telephones and facial features. One person was able to read store and restaurant signs, and another was able to observe the movements of a wild goose.
Interim results of the clinical trial were published online in
The Foundation is bolstering its commitment to restoring vision for people with the most advanced retinal diseases by investing $800,000 in the development of two emerging optogenetic therapies at the University of California, Berkeley. The funding is in addition to nearly $1.5 million that the Foundation is already providing to the Institut de la Vision in Paris for advancement of itsoptogenetics treatment. The overarching goal of all three projects is to prepare the therapies for clinical trials.
The Argus II® Retinal Prosthesis System, the first and only artificial retina to be approved by the U.S. Food and Drug Administration, will be at least partially covered under Medicare. Payment for both the system and implantation surgery will be provided. Further details of the implementation of Medicare payments — including the amounts of reimbursement and out-of-pocket costs — are forthcoming. People who are considered disabled because of vision loss may qualify for Medicare.
Researchers from the University of California, Davis (UC Davis), have launched a Phase I clinical trial of CD34+ bone marrow stem cells (BMSC) for people with retinal conditions that cause vision loss from ischemia, or loss of blood flow, and cell degeneration. Led by Dr. Susanna Park, the investigative